|
1. Biologie
|
|
|
|
|
3.1 Tabac
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
Melanoma Immunotherapy Significantly Improved with Peptide Bath [GEN]
|
|
|
|
|
|
ow,
researchers at the Medical University of South Carolina (MUSC) and
Loyola University have demonstrated that culturing T cells in the
presence of the peptide N-acetyl cysteine (NAC) before they are infused
as immunotherapy improves effectiveness and outcomes in a preclinical
model of melanoma.
|
|
|
|
|
|
|
J&J eyes immuno-oncology with 15 R&D assets [FierceBiotech]
|
|
|
|
|
|
In
the longer term, the pharma is also making some overtures in
immuno-oncology, an area that hasn’t explicitly been a major part of its
strategy. J&J has been investing in “four critical areas including
vaccines, T cell checkpoint inhibitors, T cell redirection and myeloid
mechanisms of action,” said the company’s global head of pharmaceutical
R&D, Dr. William Hait.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
AstraZeneca backs ADC in $105M to support 6 clinical oncology candidates [FierceBiotech]
|
|
|
|
|
|
ADC
already has a pair of clinical-stage programs, ADCT-301 and ADCT-402,
which are in four clinical trials in sub-types of lymphoma and leukemia.
It expects to add another two programs to the clinic, this time in
solid tumors, later this year and early next year. Within the next 18
months, the startup is aiming for an ambitious six clinical development
programs.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
CRISPR Therapeutics Raises $56M In IPO, Half Its Rivals’ Haul [Xconomy]
|
|
|
|
|
|
CRISPR
Therapeutics is founded upon the work of Emmanuelle Charpentier, a
French scientist who published key work in 2012 with Berkeley’s Jennifer
Doudna. The battle, which could last years, is currently before a
special court at the U.S. Patent and Trademark Office, with the
occasional document or accusation causing a public stir.
|
|
|
|
|
|
|
Gene editing loses its sizzle. CRISPR Therapeutics IPO debuts beneath the range [EndPoints]
|
|
|
|
|
|
Some
of the bloom has come off the rose of gene editing. CRISPR Therapeutics
had to accept $14 a share to launch its IPO, a bit below the range that
it had set for itself. And that had to be a disappointing debut after
rivals Editas and Intellia were both able to fire off hot offerings
earlier in the year — though they have also been feeling the chill more
recently.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
Roche's lung cancer drug wins U.S. approval [Reuters]
|
|
|
|
|
|
Analysts
estimate Tecentriq's annual sales across all cancers - it is already
approved for bladder cancer and will seek approval for more indications -
will reach $4 billion in 2021, according to consensus figures compiled
by Thomson Reuters.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
Treat pharma as a utility, and 10 other ways states can lower drug prices [STAT]
|
|
|
|
|
|
There
is no particular ranking of the 11 proposals made, but at the top of
the list is transparency, an issue that has emerged in state legislation
around the country. The bills would require drug makers to justify
price hikes when prices rise above a certain threshold, or provide
breakdowns of their various costs for certain medicines. Only Vermont,
however, has passed such a bill into law.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.7.2 Applis
|
|
|
Celgene partners to develop ResearchKit app for observational study [FierceBiotech]
|
|
|
|
|
|
The
iPhone ResearchKit app will aim to better understand the experience of
patients living with chronic anemia that’s due to myelodysplastic
syndromes (MDS) or beta-thalassemia. The partners will work with patient
groups the MDS Foundation and Cooley's Anemia Foundation to best define
the necessary elements to capture that are relevant to patients.
|
|
|
|
|
|
|
6.8 Communication
|
|
|